NYSE:PRGO

Perrigo Competitors

$41.08
+0.70 (+1.73 %)
(As of 04/15/2021 01:01 PM ET)
Add
Compare
Today's Range
$40.70
Now: $41.08
$41.43
50-Day Range
$40.15
MA: $41.29
$42.65
52-Week Range
$38.20
Now: $41.08
$58.83
Volume6,730 shs
Average Volume1.39 million shs
Market Capitalization$5.49 billion
P/E RatioN/A
Dividend Yield2.37%
Beta1.18

Competitors

Perrigo (NYSE:PRGO) Vs. JNJ, PFE, MRK, ABBV, LLY, and BMY

Should you be buying PRGO stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Perrigo, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), and Bristol-Myers Squibb (BMY).

Johnson & Johnson (NYSE:JNJ) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk and analyst recommendations.

Volatility & Risk

Johnson & Johnson has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Institutional and Insider Ownership

67.3% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 82.7% of Perrigo shares are owned by institutional investors. 0.3% of Johnson & Johnson shares are owned by company insiders. Comparatively, 0.3% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Johnson & Johnson and Perrigo's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.06 billion5.18$15.12 billion$8.6818.61
Perrigo$4.84 billion1.13$146.10 million$4.0310.19

Johnson & Johnson has higher revenue and earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Johnson & Johnson and Perrigo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson21.01%34.64%13.40%
Perrigo-0.13%9.78%4.92%

Dividends

Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.5%. Perrigo pays an annual dividend of $0.96 per share and has a dividend yield of 2.3%. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Perrigo pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 59 consecutive years and Perrigo has raised its dividend for 1 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Johnson & Johnson and Perrigo, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson031102.79
Perrigo04102.20

Johnson & Johnson currently has a consensus price target of $180.6429, indicating a potential upside of 11.85%. Perrigo has a consensus price target of $52.00, indicating a potential upside of 26.55%. Given Perrigo's higher probable upside, analysts clearly believe Perrigo is more favorable than Johnson & Johnson.

Summary

Johnson & Johnson beats Perrigo on 12 of the 17 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends.

Institutional & Insider Ownership

67.4% of Pfizer shares are owned by institutional investors. Comparatively, 82.7% of Perrigo shares are owned by institutional investors. 0.1% of Pfizer shares are owned by company insiders. Comparatively, 0.3% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Pfizer and Perrigo, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer010302.23
Perrigo04102.20

Pfizer currently has a consensus price target of $38.5714, suggesting a potential upside of 2.75%. Perrigo has a consensus price target of $52.00, suggesting a potential upside of 26.55%. Given Perrigo's higher probable upside, analysts plainly believe Perrigo is more favorable than Pfizer.

Risk and Volatility

Pfizer has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Profitability

This table compares Pfizer and Perrigo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer17.85%24.88%9.32%
Perrigo-0.13%9.78%4.92%

Earnings & Valuation

This table compares Pfizer and Perrigo's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$51.75 billion4.05$16.27 billion$2.9512.73
Perrigo$4.84 billion1.13$146.10 million$4.0310.19

Pfizer has higher revenue and earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Dividends

Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 4.2%. Perrigo pays an annual dividend of $0.96 per share and has a dividend yield of 2.3%. Pfizer pays out 52.9% of its earnings in the form of a dividend. Perrigo pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has raised its dividend for 1 consecutive years and Perrigo has raised its dividend for 1 consecutive years.

Summary

Pfizer beats Perrigo on 10 of the 16 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.4%. Perrigo pays an annual dividend of $0.96 per share and has a dividend yield of 2.3%. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Perrigo pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has raised its dividend for 1 consecutive years and Perrigo has raised its dividend for 1 consecutive years.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Merck & Co., Inc. and Perrigo, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.021102.85
Perrigo04102.20

Merck & Co., Inc. presently has a consensus target price of $96.2727, indicating a potential upside of 25.85%. Perrigo has a consensus target price of $52.00, indicating a potential upside of 26.55%. Given Perrigo's higher possible upside, analysts clearly believe Perrigo is more favorable than Merck & Co., Inc..

Profitability

This table compares Merck & Co., Inc. and Perrigo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.24.33%53.83%16.83%
Perrigo-0.13%9.78%4.92%

Earnings & Valuation

This table compares Merck & Co., Inc. and Perrigo's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$46.84 billion4.13$9.84 billion$5.1914.74
Perrigo$4.84 billion1.13$146.10 million$4.0310.19

Merck & Co., Inc. has higher revenue and earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Merck & Co., Inc. has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.

Institutional and Insider Ownership

72.9% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 82.7% of Perrigo shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 0.3% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Merck & Co., Inc. beats Perrigo on 11 of the 16 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Perrigo (NYSE:PRGO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.9%. Perrigo pays an annual dividend of $0.96 per share and has a dividend yield of 2.3%. AbbVie pays out 58.2% of its earnings in the form of a dividend. Perrigo pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has raised its dividend for 49 consecutive years and Perrigo has raised its dividend for 1 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares AbbVie and Perrigo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie18.16%439.24%13.22%
Perrigo-0.13%9.78%4.92%

Earnings and Valuation

This table compares AbbVie and Perrigo's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$33.27 billion5.66$7.88 billion$8.9411.93
Perrigo$4.84 billion1.13$146.10 million$4.0310.19

AbbVie has higher revenue and earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

AbbVie has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for AbbVie and Perrigo, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie121302.75
Perrigo04102.20

AbbVie presently has a consensus price target of $115.75, suggesting a potential upside of 8.44%. Perrigo has a consensus price target of $52.00, suggesting a potential upside of 26.55%. Given Perrigo's higher probable upside, analysts plainly believe Perrigo is more favorable than AbbVie.

Insider & Institutional Ownership

67.5% of AbbVie shares are owned by institutional investors. Comparatively, 82.7% of Perrigo shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.3% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

AbbVie beats Perrigo on 12 of the 17 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Volatility & Risk

Eli Lilly and has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Dividends

Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.8%. Perrigo pays an annual dividend of $0.96 per share and has a dividend yield of 2.3%. Eli Lilly and pays out 56.3% of its earnings in the form of a dividend. Perrigo pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and has increased its dividend for 1 consecutive years and Perrigo has increased its dividend for 1 consecutive years. Perrigo is clearly the better dividend stock, given its higher yield and lower payout ratio.

Earnings and Valuation

This table compares Eli Lilly and and Perrigo's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and$22.32 billion8.00$8.32 billion$6.0430.83
Perrigo$4.84 billion1.13$146.10 million$4.0310.19

Eli Lilly and has higher revenue and earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Eli Lilly and and Perrigo, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eli Lilly and041102.73
Perrigo04102.20

Eli Lilly and presently has a consensus price target of $196.40, suggesting a potential upside of 5.52%. Perrigo has a consensus price target of $52.00, suggesting a potential upside of 26.55%. Given Perrigo's higher probable upside, analysts clearly believe Perrigo is more favorable than Eli Lilly and.

Insider & Institutional Ownership

75.6% of Eli Lilly and shares are held by institutional investors. Comparatively, 82.7% of Perrigo shares are held by institutional investors. 0.1% of Eli Lilly and shares are held by insiders. Comparatively, 0.3% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Eli Lilly and and Perrigo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eli Lilly and24.01%166.45%15.18%
Perrigo-0.13%9.78%4.92%

Summary

Eli Lilly and beats Perrigo on 10 of the 16 factors compared between the two stocks.

Perrigo (NYSE:PRGO) and Bristol-Myers Squibb (NYSE:BMY) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Profitability

This table compares Perrigo and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Perrigo-0.13%9.78%4.92%
Bristol-Myers Squibb-0.11%27.48%10.77%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Perrigo and Bristol-Myers Squibb, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Perrigo04102.20
Bristol-Myers Squibb021312.94

Perrigo presently has a consensus price target of $52.00, indicating a potential upside of 26.55%. Bristol-Myers Squibb has a consensus price target of $74.60, indicating a potential upside of 15.44%. Given Perrigo's higher possible upside, analysts plainly believe Perrigo is more favorable than Bristol-Myers Squibb.

Risk & Volatility

Perrigo has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.

Institutional and Insider Ownership

82.7% of Perrigo shares are held by institutional investors. Comparatively, 72.4% of Bristol-Myers Squibb shares are held by institutional investors. 0.3% of Perrigo shares are held by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Perrigo and Bristol-Myers Squibb's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.84 billion1.13$146.10 million$4.0310.19
Bristol-Myers Squibb$26.15 billion5.52$3.44 billion$4.6913.77

Bristol-Myers Squibb has higher revenue and earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Dividends

Perrigo pays an annual dividend of $0.96 per share and has a dividend yield of 2.3%. Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.0%. Perrigo pays out 23.8% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Perrigo has raised its dividend for 1 consecutive years and Bristol-Myers Squibb has raised its dividend for 1 consecutive years.

Summary

Bristol-Myers Squibb beats Perrigo on 12 of the 17 factors compared between the two stocks.


Perrigo Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.7$161.54+1.0%$421.02 billion$82.06 billion25.40Upcoming Earnings
News Coverage
Pfizer logo
PFE
Pfizer
2.3$37.55+1.0%$207.32 billion$51.75 billion24.23Analyst Revision
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.2$76.52+0.2%$193.32 billion$46.84 billion16.93Increase in Short Interest
Analyst Revision
AbbVie logo
ABBV
AbbVie
2.8$106.63+0.7%$186.90 billion$33.27 billion22.54Analyst Revision
Eli Lilly and logo
LLY
Eli Lilly and
2.1$186.24+1.7%$175.50 billion$22.32 billion30.43Analyst Revision
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$64.57+1.2%$142.55 billion$26.15 billion-586.95Analyst Upgrade
Decrease in Short Interest
Analyst Revision
Zoetis logo
ZTS
Zoetis
2.2$165.10+1.2%$77.46 billion$6.26 billion48.99Increase in Short Interest
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$41.87+0.6%$25.57 billionN/A0.00Increase in Short Interest
Analyst Revision
News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$94.02+2.7%$20.49 billion$1.30 billion25.69Insider Selling
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$168.59+1.3%$9.37 billion$2.16 billion53.18Analyst Report
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.33+1.0%$3.49 billion$114.62 million-7.79Analyst Report
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$65.95+5.3%$3.05 billion$421.03 million23.22Analyst Report
Analyst Revision
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$23.05+0.4%$2.69 billion$306.49 million25.90
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.5$31.98+0.3%$1.69 billion$392.76 million13.27Analyst Upgrade
Analyst Revision
News Coverage
Endo International logo
ENDP
Endo International
1.3$6.15+2.0%$1.45 billion$2.91 billion-9.04
Omeros logo
OMER
Omeros
1.4$17.85+1.6%$1.09 billion$111.81 million-7.50
Zogenix logo
ZGNX
Zogenix
1.7$19.23+1.0%$1.08 billion$3.65 million-2.02
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$8.09+3.8%$393.90 million$16.54 million-3.29News Coverage
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.50+1.1%$348.98 million$111.39 million25.00
Lannett logo
LCI
Lannett
2.0$4.82+3.3%$206.18 million$545.74 million-6.69
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$4.35+1.8%$177.46 million$15.96 million-2.64
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.9$3.06+2.0%$45.66 million$47.53 million-13.91
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.